Total Payments
$44,592
2023 Payments
$132.47
Companies
12
Transactions
218
Medicare Patients
1,172
Medicare Billing
$196,927
Payment Breakdown by Category
Other$39,340 (88.2%)
Food & Beverage$4,078 (9.1%)
Travel$1,106 (2.5%)
Education$67.58 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $39,340 | 28 | 88.2% |
| Food and Beverage | $4,078 | 184 | 9.1% |
| Travel and Lodging | $1,106 | 3 | 2.5% |
| Education | $67.58 | 3 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan Inc. | $41,150 | 66 | $0 (2018) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,206 | 5 | $0 (2017) |
| Sunovion Pharmaceuticals Inc. | $761.33 | 49 | $0 (2021) |
| Neurocrine Biosciences, Inc. | $651.49 | 32 | $0 (2023) |
| Lundbeck LLC | $461.92 | 39 | $0 (2018) |
| Otsuka America Pharmaceutical, Inc. | $230.75 | 17 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $38.40 | 4 | $0 (2018) |
| ABBVIE INC. | $25.48 | 2 | $0 (2022) |
| IDORSIA PHARMACEUTICALS US INC | $23.31 | 1 | $0 (2023) |
| ITI, Inc. | $19.29 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $132.47 | 5 | Neurocrine Biosciences, Inc. ($109.16) |
| 2022 | $191.24 | 9 | Neurocrine Biosciences, Inc. ($146.47) |
| 2021 | $292.25 | 15 | Neurocrine Biosciences, Inc. ($255.53) |
| 2020 | $26.63 | 1 | Neurocrine Biosciences, Inc. ($26.63) |
| 2018 | $37,195 | 108 | Allergan Inc. ($36,391) |
| 2017 | $6,754 | 80 | Allergan Inc. ($4,759) |
All Payment Transactions
218 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/14/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $31.90 | General |
| Category: Neuropsychiatry | ||||||
| 05/10/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $23.31 | General |
| Category: INSOMNIA | ||||||
| 04/19/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: Neuropsychiatry | ||||||
| 02/25/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $28.07 | General |
| Category: Neuropsychiatry | ||||||
| 01/27/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: Neuropsychiatry | ||||||
| 12/14/2022 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: PSYCHIATRY | ||||||
| 07/13/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.21 | General |
| Category: NEUROSCIENCE | ||||||
| 06/08/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: Neuropsychiatry | ||||||
| 05/11/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $32.27 | General |
| Category: Neuropsychiatry | ||||||
| 04/13/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: Neuropsychiatry | ||||||
| 03/23/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.27 | General |
| Category: NEUROSCIENCE | ||||||
| 03/09/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $34.78 | General |
| Category: Neuropsychiatry | ||||||
| 02/17/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: Neuropsychiatry | ||||||
| 02/09/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: Neuropsychiatry | ||||||
| 12/08/2021 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: CNS | ||||||
| 12/01/2021 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $29.81 | General |
| Category: NEUROLOGY | ||||||
| 11/19/2021 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $30.32 | General |
| Category: NEUROLOGY | ||||||
| 11/17/2021 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $12.32 | General |
| Category: CNS | ||||||
| 10/20/2021 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: NEUROLOGY | ||||||
| 10/13/2021 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $10.15 | General |
| Category: CNS | ||||||
| 09/15/2021 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $23.66 | General |
| Category: NEUROLOGY | ||||||
| 08/11/2021 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $22.63 | General |
| Category: NEUROLOGY | ||||||
| 07/28/2021 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: NEUROLOGY | ||||||
| 06/23/2021 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $8.37 | General |
| Category: NEUROLOGY | ||||||
| 05/19/2021 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $25.52 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 280 | 644 | $133,165 | $52,137 |
| 2022 | 5 | 301 | 624 | $108,615 | $54,302 |
| 2021 | 6 | 269 | 577 | $100,557 | $52,983 |
| 2020 | 8 | 322 | 601 | $90,227 | $37,504 |
Total Patients
1,172
Total Services
2,446
Medicare Billing
$196,927
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 86 | 271 | $72,367 | $29,813 | 41.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 77 | 134 | $22,481 | $9,933 | 44.2% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 62 | 163 | $26,140 | $7,910 | 30.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 38 | 59 | $5,487 | $2,735 | 49.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 17 | 17 | $6,690 | $1,746 | 26.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 115 | 312 | $69,180 | $35,522 | 51.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 62 | 106 | $15,375 | $7,614 | 49.5% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 58 | 114 | $11,400 | $5,942 | 52.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 27 | 44 | $6,204 | $2,313 | 37.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 28 | 37 | $3,441 | $2,005 | 58.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 11 | 11 | $3,015 | $906.56 | 30.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 105 | 272 | $60,475 | $31,885 | 52.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 66 | 164 | $23,220 | $12,851 | 55.3% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 32 | 47 | $4,700 | $2,501 | 53.2% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 19 | 19 | $3,370 | $2,143 | 63.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 21 | 34 | $4,729 | $1,883 | 39.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 26 | 41 | $4,063 | $1,721 | 42.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 139 | 364 | $57,575 | $24,473 | 42.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 56 | 73 | $9,709 | $3,437 | 35.4% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 34 | 53 | $5,300 | $2,684 | 50.6% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2020 | 18 | 18 | $3,315 | $2,076 | 62.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 23 | 32 | $4,272 | $1,646 | 38.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 20 | 21 | $7,011 | $1,614 | 23.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 19 | 24 | $2,357 | $1,182 | 50.2% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 13 | 16 | $688.00 | $393.44 | 57.2% |
About Dr. Claudia Baldassano, MD
Dr. Claudia Baldassano, MD is a Psychiatry healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1598772048.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Claudia Baldassano, MD has received a total of $44,592 in payments from pharmaceutical and medical device companies, with $132.47 received in 2023. These payments were reported across 218 transactions from 12 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($39,340).
As a Medicare-enrolled provider, Baldassano has provided services to 1,172 Medicare beneficiaries, totaling 2,446 services with total Medicare billing of $196,927. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Philadelphia, PA
- Active Since 08/01/2006
- Last Updated 09/30/2011
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1598772048
Products in Payments
- VRAYLAR (Drug) $41,175
- ABILIFY TABLET (Drug) $1,206
- LATUDA (Drug) $723.07
- INGREZZA (Drug) $651.49
- REXULTI (Drug) $625.55
- Trintellix (Drug) $51.03
- ABILIFY MAINTENA (Drug) $41.01
- Utibron (Drug) $38.26
- TRINTELLIX (Drug) $26.11
- QUVIVIQ (Drug) $23.31
- CAPLYTA (Drug) $19.29
- NUEDEXTA (Drug) $11.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Philadelphia
Daniel Weintraub, Md, MD
Psychiatry — Payments: $614,211
Psychiatry $614,211
Dr. Michael Thase, Md, MD
Psychiatry — Payments: $418,426
Psychiatry $418,426
Dr. Karl Doghramji, Md, MD
Psychiatry — Payments: $130,409
Psychiatry $130,409
Richard Jaffe, Md, MD
Psychiatry — Payments: $126,747
Psychiatry $126,747
Kyle Kampman, Md, MD
Psychiatry — Payments: $118,739
Psychiatry $118,739
Ramesh Eluri, M.d, M.D
Psychiatry — Payments: $88,982
Psychiatry $88,982